CZ280328B6 - Deriváty aromatických aminoalkoholů, mající antid iabetické a antiobezitní vlastnosti, jejich přípr ava a jejich terapeutické využití - Google Patents

Deriváty aromatických aminoalkoholů, mající antid iabetické a antiobezitní vlastnosti, jejich přípr ava a jejich terapeutické využití Download PDF

Info

Publication number
CZ280328B6
CZ280328B6 CS923436A CS343692A CZ280328B6 CZ 280328 B6 CZ280328 B6 CZ 280328B6 CS 923436 A CS923436 A CS 923436A CS 343692 A CS343692 A CS 343692A CZ 280328 B6 CZ280328 B6 CZ 280328B6
Authority
CZ
Czechia
Prior art keywords
groups
group
carbon atoms
atom
hydroxy
Prior art date
Application number
CS923436A
Other languages
Czech (cs)
English (en)
Inventor
Takashi Fujita
Takao Yoshioka
Hiroyoshi Horikoshi
Shinji Yoshioka
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of CZ343692A3 publication Critical patent/CZ343692A3/cs
Publication of CZ280328B6 publication Critical patent/CZ280328B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CS923436A 1991-11-20 1992-11-19 Deriváty aromatických aminoalkoholů, mající antid iabetické a antiobezitní vlastnosti, jejich přípr ava a jejich terapeutické využití CZ280328B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30458191 1991-11-20

Publications (2)

Publication Number Publication Date
CZ343692A3 CZ343692A3 (en) 1993-12-15
CZ280328B6 true CZ280328B6 (cs) 1995-12-13

Family

ID=17934718

Family Applications (2)

Application Number Title Priority Date Filing Date
CS923436A CZ280328B6 (cs) 1991-11-20 1992-11-19 Deriváty aromatických aminoalkoholů, mající antid iabetické a antiobezitní vlastnosti, jejich přípr ava a jejich terapeutické využití
CZ95345A CZ34595A3 (en) 1991-11-20 1992-11-19 Intermediates for preparing aromatic aminoalcohol derivatives and process for preparing thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CZ95345A CZ34595A3 (en) 1991-11-20 1992-11-19 Intermediates for preparing aromatic aminoalcohol derivatives and process for preparing thereof

Country Status (23)

Country Link
US (3) US5977374A (enExample)
EP (1) EP0543662B1 (enExample)
JP (2) JP2654323B2 (enExample)
KR (1) KR0149679B1 (enExample)
CN (3) CN1033750C (enExample)
AT (1) ATE143002T1 (enExample)
AU (2) AU655689B2 (enExample)
CA (1) CA2083323A1 (enExample)
CZ (2) CZ280328B6 (enExample)
DE (1) DE69213892T2 (enExample)
DK (1) DK0543662T3 (enExample)
ES (1) ES2094308T3 (enExample)
FI (1) FI925255A7 (enExample)
GR (1) GR3021245T3 (enExample)
HK (1) HK218496A (enExample)
HU (1) HUT66816A (enExample)
IL (3) IL103825A (enExample)
MX (1) MX9206740A (enExample)
NO (1) NO179246C (enExample)
NZ (1) NZ245188A (enExample)
RU (2) RU2095344C1 (enExample)
TW (2) TW290543B (enExample)
ZA (1) ZA928960B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106877A (en) * 1992-09-10 1998-03-10 Lilly Co Eli Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments
CA2145257A1 (en) * 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
NO305987B1 (no) * 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
AU2737295A (en) * 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9525121D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
GB9525177D0 (en) * 1995-12-08 1996-02-07 Glaxo Group Ltd Chemical compounds
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
DE69625795T2 (de) * 1996-04-09 2003-08-14 Dr. Reddy's Laboratories Ltd., Hyderabad Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven Eigenschaften, Verfahren zu deren Herstellung und pharmazeutischen Zusammenstellungen, die sie enthalten
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US6114526A (en) 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
BR9711098B1 (pt) 1996-07-01 2011-10-04 compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
GB9706707D0 (en) * 1997-04-02 1997-05-21 Glaxo Group Ltd Chemical compounds
JPH10338679A (ja) * 1997-04-08 1998-12-22 Mitsubishi Rayon Co Ltd チアゾリジン誘導体の製造方法
HUP9702411A2 (hu) * 1997-12-11 2000-03-28 Gyógyszerkutató Intézet Kft. Fenoxi-alkil-amin-származékok és a vegyületeket tartalmazó antiaritmiás hatású gyógyszerkészítmények
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6006419A (en) * 1998-09-01 1999-12-28 Millitech Corporation Synthetic resin transreflector and method of making same
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
GB9929297D0 (en) * 1999-12-11 2000-02-02 Glaxo Group Ltd Process
EP1283054A4 (en) * 2000-03-17 2006-04-12 Ajinomoto Kk MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
BR0112484A (pt) * 2000-07-13 2003-09-23 Sankyo Co Composto ou um seu sal, éster ou outro derivado farmacologicamente aceitável, composição farmacêutica, uso de um composto ou de um seu sal, éster ou outro derivado farmacologicamente aceitável, e, processo para a preparação do mesmo
SK4612003A3 (en) 2000-10-20 2004-06-08 Pfizer Prod Inc Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
JP2004527530A (ja) * 2001-04-05 2004-09-09 スミスクライン・ビーチャム・コーポレイション ペプチドデホルミラーゼ阻害物質
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
WO2003010157A1 (en) * 2001-07-23 2003-02-06 Dr. Reddy's Research Foundation Dioxane derivatives and a process for their preparation
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
CA2471646A1 (en) 2002-02-27 2003-09-04 Yong Tao Processes and intermediates useful in preparing .beta.3-adrenergic receptor agonists
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
WO2005061433A2 (en) * 2003-12-23 2005-07-07 Astellas Pharma Inc. Aminoalcohol derivatives
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
KR20100084604A (ko) 2007-10-24 2010-07-27 쮸 시아오잉 감아올림 스크린 장치
US8716528B2 (en) 2007-11-01 2014-05-06 Howard Florey Institute Aryloxy amine compounds and their use as sodium channel modulators
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US9968531B2 (en) 2015-08-05 2018-05-15 Dupont Tate & Lyle Bio Products Company, Llc Deodorants containing 1,3-propanediol
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
WO2019190172A1 (ko) * 2018-03-26 2019-10-03 주식회사 프로텍바이오 신규한 화합물 및 이를 포함하는 비만 또는 대사증후군의 예방 또는 치료용 약학적 조성물
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) * 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3976783A (en) * 1970-07-18 1976-08-24 Pfizer Inc. Method of stimulating the heart employing ureido substituted phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives
GB1551260A (en) * 1976-02-09 1979-08-30 Allen & Hanburys Ltd Phenylethanolamine derivatives
EP0006735B1 (en) * 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
DE3061334D1 (en) * 1979-06-16 1983-01-20 Beecham Group Plc Ethanamine derivatives, their preparation and use in pharmaceutical compositions
EP0021636B1 (en) * 1979-06-16 1982-12-01 Beecham Group Plc Secondary amines, their preparation and use in pharmaceutical compositions
DE3062216D1 (en) * 1979-09-06 1983-04-07 Beecham Group Plc Cinnamic acid derivatives, their preparation, and pharmaceutical compositions containing them
DE3368258D1 (en) * 1982-07-16 1987-01-22 Beecham Group Plc 2-aminoethyl ether derivatives, processes for their preparation and pharmaceutical compositions containing them
GB8528633D0 (en) * 1985-11-21 1985-12-24 Beecham Group Plc Compounds
GB8620951D0 (en) * 1986-08-29 1986-10-08 Beecham Group Plc Compounds
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8910374D0 (en) * 1989-05-05 1989-06-21 Ici Plc Chemical compounds
US5037842A (en) * 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
HUT70421A (en) * 1991-07-30 1995-10-30 Yamanouchi Pharma Co Ltd Novel bisoxazolidine derivatives pharmaceutical compositions containing them and process for preparing them
GB9313574D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
NZ245188A (en) 1994-07-26
ES2094308T3 (es) 1997-01-16
AU655689B2 (en) 1995-01-05
AU670007B2 (en) 1996-06-27
DK0543662T3 (enExample) 1997-03-03
JP2654323B2 (ja) 1997-09-17
TW233294B (enExample) 1994-11-01
KR0149679B1 (ko) 1998-10-15
US5635534A (en) 1997-06-03
FI925255L (fi) 1993-05-21
AU2849392A (en) 1993-05-27
NO924440D0 (no) 1992-11-18
NO179246B (no) 1996-05-28
NO179246C (no) 1996-09-04
JPH0625118A (ja) 1994-02-01
EP0543662B1 (en) 1996-09-18
GR3021245T3 (en) 1997-01-31
HUT66816A (en) 1995-01-30
FI925255A7 (fi) 1993-05-21
IL110804A (en) 1997-07-13
FI925255A0 (fi) 1992-11-19
CN1151401A (zh) 1997-06-11
US5576340A (en) 1996-11-19
KR930009982A (ko) 1993-06-21
EP0543662A2 (en) 1993-05-26
IL103825A0 (en) 1993-04-04
CZ343692A3 (en) 1993-12-15
NO924440L (no) 1993-05-21
CN1054846C (zh) 2000-07-26
DE69213892T2 (de) 1997-04-17
IL103825A (en) 1998-04-05
CN1106396A (zh) 1995-08-09
CN1073428A (zh) 1993-06-23
ATE143002T1 (de) 1996-10-15
EP0543662A3 (en) 1993-08-11
US5977374A (en) 1999-11-02
CN1034497C (zh) 1997-04-09
HK218496A (en) 1996-12-27
IL110804A0 (en) 1994-11-11
CZ280820B6 (cs) 1996-04-17
AU7751894A (en) 1995-01-12
TW290543B (enExample) 1996-11-11
JPH09188669A (ja) 1997-07-22
CZ34595A3 (en) 1996-04-17
RU2095344C1 (ru) 1997-11-10
ZA928960B (en) 1993-05-19
RU2081113C1 (ru) 1997-06-10
CN1033750C (zh) 1997-01-08
RU94036004A (ru) 1996-07-10
CA2083323A1 (en) 1993-05-21
DE69213892D1 (de) 1996-10-24
HU9203638D0 (en) 1993-01-28
MX9206740A (es) 1993-05-31
JP2991985B2 (ja) 1999-12-20

Similar Documents

Publication Publication Date Title
CZ280328B6 (cs) Deriváty aromatických aminoalkoholů, mající antid iabetické a antiobezitní vlastnosti, jejich přípr ava a jejich terapeutické využití
EP0590793B1 (en) Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
JP3490704B2 (ja) チアゾールおよびオキサゾール誘導体ならびにそれらの医薬的使用
JP3906935B2 (ja) Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
SK17682000A3 (sk) Deriváty kyseliny 3-aryl-2-hydroxypropiónovej
HUT71231A (en) Thiazolidine and oxazolidine derivatives
US6288096B1 (en) Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
HK1011979B (en) Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses
JPH07330710A (ja) 芳香族化合物
HK1071748B (en) New heterocyclic oxime compounds, a process for their preparation and pharmaceutical compositions containing them
HK1071748A1 (zh) 新的雜環肟化合物、它們的製備方法和含有它們的藥物組合物

Legal Events

Date Code Title Description
IF00 In force as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20031119